Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer

BACKGROUND: Homologous recombination deficiency (HRD) is a molecular biomarker for administrating PARP inhibitor (PARPi) or platinum-based (Pt) chemotherapy. The most well-studied mechanism of causing HRD is pathogenic BRCA1/2 mutations, while HRD phenotype is also present in patients without BRCA1/...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Hao, Feng, Zheng, Ma, Yutong, Liu, Rui, Ou, Qiuxiang, Guo, Qinhao, Shen, Yi, Wu, Xue, Shao, Yang, Bao, Hua, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109318/
https://www.ncbi.nlm.nih.gov/pubmed/35578198
http://dx.doi.org/10.1186/s12885-022-09602-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109318/
https://www.ncbi.nlm.nih.gov/pubmed/35578198
http://dx.doi.org/10.1186/s12885-022-09602-4

Ejemplares similares